BIO-
Bio-Rad Laboratories Inc
NYSE: BIO-B · HEALTHCARE · MEDICAL DEVICES
$365.08
+0.00% today
Updated 2026-09-11
Market cap
$9.76B
P/E ratio
44.47
P/S ratio
3.77x
EPS (TTM)
$8.21
Dividend yield
—
52W range
$245 – $402
Volume
0.0M
Bio-Rad Laboratories Inc (BIO-B) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
0 of 8
Last 8 quarters
Avg EPS surprise
—
Last 4 quarters
Revenue YoY growth
-0.1%
Most recent quarter
EPS YoY growth
+18.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-3.2%
Last 4 reports
Positive reaction rate
0%
0 of 4 quarters
Largest single-day move
-12.9%
2026-02-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-08-04 | $13.85 | — | $337.00 | $337.00 | +0.0% |
| 2026-04-30 | $-19.55 | — | $299.45 | $299.45 | +0.0% |
| 2026-02-12 | $26.65 | — | $295.05 | $257.05 | -12.9% |
| 2025-10-28 | $-12.70 | — | $321.12 | $321.12 | +0.0% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-06-30 | — | $13.85 | — | $651.00M | -0.1% |
| 2026-03-31 | — | $-19.55 | — | $592.10M | +1.1% |
| 2025-12-31 | — | $26.65 | — | $693.20M | +3.9% |
| 2025-09-30 | — | $-12.70 | — | $653.00M | +0.5% |
| 2025-06-30 | — | $11.67 | — | $651.60M | +2.1% |
| 2025-03-31 | — | $2.29 | — | $585.40M | -4.2% |
| 2024-12-31 | — | $-25.57 | — | $667.48M | -2.0% |
| 2024-09-30 | — | $23.34 | — | $649.73M | — |
| 2024-06-30 | — | $-76.26 | — | $638.48M | — |
| 2024-03-31 | $2.99 | $13.45 | +349.9% | $610.82M | — |
| 2023-12-31 | $2.84 | $3.10 | +9.2% | $681.18M | — |
Frequently asked questions
Has Bio-Rad Laboratories Inc beaten earnings estimates?
Bio-Rad Laboratories Inc has beaten Wall Street EPS estimates in 0 of its last 8 quarterly reports. A consistent beat record suggests management guides conservatively and the business has predictable momentum, which tends to support the stock through earnings season.
How does BIO-B stock react to earnings?
BIO-B has moved an average of -3.2% the day after earnings over its last 4 reports, finishing higher after 0 of them. Next-day moves show how the market digests results in the short term, and repeated dips on strong reports usually mean expectations were already priced in.
What is Bio-Rad Laboratories Inc's revenue growth rate?
Bio-Rad Laboratories Inc reported year-over-year revenue growth of -0.1% in its most recent quarter, with EPS up +18.7%. EPS outpacing revenue is operating leverage at work, meaning profit is compounding faster than sales.